Encephalopathy caused by lanthanum carbonate

NDT Plus

Volumn 4, Issue 3, 2011, Pages 192-194

  Fraile, Pilar ^a   Cacharro, Luis Maria ^b   Garcia Cosmes, Pedro ^a   Rosado, Consolacion ^a   Tabernero, Jose Matias ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

Author keywords

chronic kidney disease; encephalopathy; lanthanum carbonate; phosphate binding agent

Indexed keywords

LANTHANUM CARBONATE; PROTEIN;

ACUTE CONFUSION; ADULT; ARTICLE; BARRETT ESOPHAGUS; BRAIN DISEASE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CONDUCT DISORDER; DELIRIUM; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG TOLERANCE; DRUG WITHDRAWAL; ESOPHAGUS VARICES; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; LIVER DISEASE; MALE; MINERAL METABOLISM; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; THYROID NODULE; WEIGHT REDUCTION;

EID: 79958100217     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfr003     Document Type: Article

References (10)

1. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312-1324
2. Van Landeghem GF, D'Haese PC, Lamberts LV et al. Aluminium speciation in cerebrospinal fluid of acutely aluminium-intoxicated dialysis patients before and after desferrioxamine treatment; a step in the understanding of the element's neurotoxicity. Nephrol Dial Transplant 1997; 12: 1692-1698 (Pubitemid 27346299)
3. Sprague SM, Abboud H, Qiu P et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 178-185
4. Hutchison AJ, Laville M. on behalf of the SPD405-313 lanthanum study group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008; 23: 3677-3684
5. Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up. Nephrol Dial Transplant 2006; 21: 2217-2224 (Pubitemid 44295048)
6. De Leeuw K, Woestenburg A, Verbeelen D. Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis. NDT Plus 2008; 6: 412-413
7. Davis RL, Abraham JL. Lanthanum deposition in a dialysis patient. Nephrol Dial Transplant 2009; 24: 3247-3250
8. Feng L, Xiao H, He X et al. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol Lett 2006; 165: 112-120
9. Muller C, Chantrel F, Faller B. A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report. Nephrol Dial Transplant 2009; 24: 3245-3247
10. Zheng W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol 2001; 39: 711-719 (Pubitemid 34016566)